Wolfe Research starts Akero at outperform, cites MASH drug prospects

seekingalpha06-12

Wolfe Research started coverage of Akero Therapeutics (NASDAQ:AKRO) with an outperform rating, citing its drug candidate for the treatment of MASH, EFX. The investment firm said the stock's two major ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2442310770?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1155610132/image_1155610132.jpg","is_english":true,"pubTime":"2024-06-12 01:49","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2442310770","market":"sg","top_or_hot":-1,"title":"Wolfe Research starts Akero at outperform, cites MASH drug prospects","media":"seekingalpha","content":"<div>\n<p>Wolfe Research started coverage of Akero Therapeutics (NASDAQ:AKRO) with an outperform rating, citing its drug candidate for the treatment of MASH, EFX. The investment firm said the stock's two major ...</p>\n\n<a href=\"https://seekingalpha.com/news/4114927-wolfe-research-starts-akero-at-outperform-cites-mash-drug-prospects\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wolfe Research starts Akero at outperform, cites MASH drug prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWolfe Research starts Akero at outperform, cites MASH drug prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-12 01:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4114927-wolfe-research-starts-akero-at-outperform-cites-mash-drug-prospects><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wolfe Research started coverage of Akero Therapeutics (NASDAQ:AKRO) with an outperform rating, citing its drug candidate for the treatment of MASH, EFX. The investment firm said the stock's two major ...</p>\n\n<a href=\"https://seekingalpha.com/news/4114927-wolfe-research-starts-akero-at-outperform-cites-mash-drug-prospects\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/4114927-wolfe-research-starts-akero-at-outperform-cites-mash-drug-prospects","article_id":"2442310770","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1155610132/image_1155610132.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2442310770","pubTimestamp":1718128164,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Wolfe Research started coverage of Akero Therapeutics  with an outperform rating, citing its drug candidate for the treatment of MASH, EFX. The investment firm said the stock's two major drivers were whether the launch of Madrigal’s  Rezdiffra exceeds expectations and EFX succeeds clinically in the treatment of stage F4 liver fibrosis. Wolfe said it was bullish on the Rezdiffra launch, adding Madrigal will be able to “prime the market for possible competitors like AKRO.\" The firm added that EFX has “modest odds of success in F4, but upside is greater than downside.” Wolfe set its price target for the stock at $40.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc.","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","AKRO":"Akero Therapeutics"},"translate_title":"Wolfe Research以跑赢大盘的成绩启动Akero，并引用MASH药物前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":1,"MDGL":1},"content_text":"Wolfe Research started coverage of Akero Therapeutics (NASDAQ:AKRO) with an outperform rating, citing its drug candidate for the treatment of MASH, EFX. The investment firm said the stock's two major drivers were whether the launch of Madrigal’s (MDGL) Rezdiffra exceeds expectations and EFX succeeds clinically in the treatment of stage F4 liver fibrosis. Wolfe said it was bullish on the Rezdiffra launch, adding Madrigal will be able to “prime the market for possible competitors like AKRO.\" The firm added that EFX has “modest odds of success in F4, but upside is greater than downside.” Wolfe set its price target for the stock at $40.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.1","shortVersion":"4.24.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2442310770"}